omapatrilat

Also known as Omapatrilate

Omapatrilat (INN, proposed trade name Vanlev) is an experimental antihypertensive agent that was never marketed. It inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.

In the Vinony graph

Within Vinony's link graph, omapatrilat is referenced by 86 other articles, and connects out to angiotensins, amlodipine/valsartan and antihypertensive drug.

It is catalogued under topics including Abandoned drugs, ACE inhibitors and Carboxylic acids.

Its subject is documented across 5 Wikipedia language editions.

Research

281 papers

Omapatrilat. Bristol-Myers Squibb.Current opinion in investigational drugs (London, England : 2000) · 2001
Omapatrilat: a unique new agent for the treatment of cardiovascular disease.Heart disease (Hagerstown, Md.) · 2000
Omapatrilat--the story of Overture and Octave.International journal of cardiology · 2002
Recent clinical trials with omapatrilat: new developments.Current hypertension reports · 2003
Omapatrilat.Circulation · 2002

via PubMed

Wikidata facts

Mass: 408.117749

Show 3 more facts

chemical formula: C₁₉H₂₄N₂O₄S₂
canonical SMILES: C1CC(N2C(C1)SCCC(C2=O)NC(=O)C(CC3=CC=CC=C3)S)C(=O)O
isomeric SMILES: C1C[C@H](N2[C@H](C1)SCC[C@@H](C2=O)NC(=O)[C@H](CC3=CC=CC=C3)S)C(=O)O

Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

3 sections

Contents

See also
References
Further reading

It was discovered and developed by Bristol-Myers Squibb but failed in clinical trials as a potential treatment for congestive heart failure due to safety concerns about its causing angioedema.

Excerpted from Wikipedia’s “omapatrilat” article, available under the CC BY-SA 4.0 licence.